Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis

• Verfasst von: Tappeiner, Christoph [VerfasserIn]
• Verfasst von: Mesquida, Marina [VerfasserIn]
• Verfasst von: Adán, Alfredo [VerfasserIn]
• Verfasst von: Anton, Jordi [VerfasserIn]
• Verfasst von: Ramanan, Athimalaipet V. [VerfasserIn]
• Verfasst von: Carreno, Ester [VerfasserIn]
• Verfasst von: Mackensen, Friederike [VerfasserIn]
• Verfasst von: Kotaniemi, Kaisu [VerfasserIn]
• Verfasst von: Boer, Joke H. de [VerfasserIn]
• Verfasst von: Bou, Rosa [VerfasserIn]
• Verfasst von: Vicuña, Carmen García de [VerfasserIn]
• Verfasst von: Heiligenhaus, Arnd [VerfasserIn]
• Titel: Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis
• Verf.angabe: Christoph Tappeiner, Marina Mesquida, Alfredo Adán, Jordi Anton, Athimalaipet V. Ramanan, Ester Carreno, Friederike Mackensen, Kaisu Kotaniemi, Joke H. de Boer, Rosa Bou, Carmen García de Vicuña, Arnd Heiligenhaus
• E-Jahr: 2016
• Jahr: [2016]
• Umfang: 6 S.
• Fussnoten: Gesehen am 20.05.2020
• Titel Quelle: Enthalten in: The journal of rheumatology
• Ort Quelle: Toronto, Ont., 2001
• Jahr Quelle: 2016
• Band/Heft Quelle: 43(2016), 12, Seite 2183-2188
• ISSN Quelle: 1499-2752
• DOI: doi:10.3899/jrheum.160231
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: BIOLOGICS
• Sach-SW: CYSTOID MACULAR EDEMA
• Sach-SW: JUVENILE IDIOPATHIC ARTHRITIS
• Sach-SW: TOCILIZUMAB
• Sach-SW: UVEITIS
• K10plus-PPN: 1698609906

Abstract

Objective. To report on experience using the anti-interleukin 6 receptor antibody tocilizumab (TCZ) to treat severe and therapy-refractory uveitis associated with juvenile idiopathic arthritis (JIA). - Methods. Retrospective data were gathered from patients with JIA receiving TCZ treatment for uveitis. JIA and related uveitis data (disease onset, activity, structural complications, and topical and systemic antiinflammatory treatment) were evaluated at the start of TCZ (baseline) and every 3 months during TCZ therapy. - Results. A total of 17 patients (14 women) with active uveitis were included (mean age 15.3 ± 6.9 yrs, mean followup time 8.5 mos). In all patients, uveitis had been refractory to previous topical and systemic corticosteroids, methotrexate (MTX), and other synthetic and biological disease-modifying antirheumatic drugs, including ≥ 1 tumor necrosis factor-α (TNF-α) inhibitor. Uveitis inactivity was achieved in 10 patients after a mean of 5.7 months of TCZ treatment (in 3 of them, it recurred during followup) and persisted in the remaining 7 patients. By using TCZ, systemic corticosteroids or immunosuppressives could be spared in 7 patients. Macular edema was present in 5 patients at baseline and improved in all of them under TCZ treatment. Arthritis was active in 11 patients at the initial and in 6 at the final followup visit. - Conclusion. TCZ appears to represent a therapeutic option for severe JIA-associated uveitis that has been refractory to MTX and TNF-α inhibitors in selected patients. The present data indicate that inflammatory macular edema responds well to TCZ in patients with JIA-associated uveitis.